Nasometin (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal mucosa. This binding alters gene expression, suppressing the release of inflammatory mediators such as cytokines and chemokines. The result is reduced swelling, mucus production, and vascular leakage, which alleviates nasal symptoms.

The appropriate dose of Nasometin is set by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the exact instructions on the prescription label and not adjust the number of sprays without medical advice.

The safety of Nasometin in pregnancy or while breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their physician before using this medication.

To order Nasometin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both mometasone furoate (Nasometin) and fluticasone are intranasal corticosteroids with similar anti‑inflammatory actions. Mometasone is often noted for its high receptor affinity and low systemic absorption, which may translate to a favorable safety profile, especially with long‑term use. Clinical choice depends on physician preference, patient response, and formulary considerations.

Store Nasometin at room temperature, below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Nasometin is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, severe allergic reactions (anaphylaxis), adrenal suppression with extensive use, fungal infections of the nasal passages, and increased intra‑ocular pressure that could affect vision. Any sudden or severe symptoms should prompt immediate medical evaluation.

Nasometin should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. Caution is also advised for patients with active untreated nasal infections, recent nasal surgery, or those with uncontrolled glaucoma or cataracts unless specifically directed by a clinician.